

Evaluating the efficacy of speech amplification and personal communication devices in Parkinson's disease



Thea Knowles^{1,2}, Scott Adams^{1,2,3}, Allyson Page^{1,2}, Daryn Cushnie-Sparrow^{1,2}, Mandar Jog³

¹Health and Rehabilitation Sciences Program, ²School of Communication Sciences and Disorders, ³Clinical Neurological Sciences, Western University.

Background

- Parkinson's disease (PD): neurodegenerative movement disorder that affects approximately 3% of individuals over 60 (Nussbaum & Ellis, 2003).
- 70 90% of people with PD will eventually develop a speech disorder (Logemann et al., 1978).
- **Hypophonia**, or *reduced vocal loudness*, is one of the most prevalent speech symptoms associated with PD (Adams & Dykstra, 2009).
- While behavioral interventions are a promising solution for many individuals with PD and hypophonia, many others have great difficulty transferring increased loudness in their dayto-day lives due to cognitive and sensorimotor deficits associated with PD (Adams & Dykstra, 2009; Sapir 2014).
- Voice amplification devices, which increase the loudness of a person's natural voice, offer an alternative solution for many individuals. However, despite their availability, little research has been done on device options and efficacy (Bertrand, 2009; Andreetta et al., 2016)

Purpose: To compare the performance of three devices used to amplify speech loudness of people with hypophonia


Methods

Participants: 22 participant dyads; individuals with hypophonia secondary to PD (or MSA in n=2) and their primary communication partner (e.g., a spouse)

Design: Clinical crossover design involving two stages:

Stage 1, Laboratory speech tasks (Visit 1)

- PD participants read aloud sentences and described pictures in four device conditions, and in two noise conditions
- Communication partner, seated 6 m away, repeated sentences back aloud
- Recordings collected via headset microphone and 2m table microphone



Stage 2, One-week home trial periods (Visits 2-4)

- 19 participants tried out each of the three devices for a week
- Following each trial period, participants met with examiner to discuss what they did and didn't like about the devices, and to complete a series of questionnaires relating to their device impressions and the impacts on their communication.

Final Decision (Visit 4): Decide whether to keep using a device.

Devices

Wired belt-pack amplifier Chattervox

- Headset microphone
- Amplifier worn around waist

Wireless stationary amplifier Nady WA120 BT

- Headset microphone
- Pocket-sized transmitter
- Large stereo amplifier to be placed in one location



Personal communication device

Nady 351VR

- Headset microphone
- Pocket-sized transmitter
- Pocket-sized receiver connected to headphones worn by listener
- One-on-one communication

Outcome measures

Speech intelligibility: What percentage of words was correctly heard by...

- The communication partner
- Naïve listeners (n = 3)

Speech-to-noise ratio: How loud was the talker compared to the background noise during...

- Sentence reading
- Picture description


Overall preference: On a visual analog scale from low to high, what did each participant think of each device...


- Immediately after trying them in the lab
- Following the one-week trial periods at home


Final decision: At the end of the study, did the participants elect to continue using a device? Which one?


6-month follow-ups: Currently in progress!


Results











Discussion





- Clear device hierarchy through objective measures, but discrepancy between device performance measures and final preferences
- Majority of individuals elected to continue using a device following study completion; *however...*
- Device decisions did not align with device hierarchy observed in lab. Individual preferences emerged.
- Results indicate the promise of speech amplification and communication device use for hypophonia, but highlight a need to explore factors that influence preference and long-term use

References

- Adams, S. G. & Dykstra, A. D. (2009). Hypokinetic dysarthria. In M. R. McNeil (Ed.), Clinical management of sensorimotor speech disorders. New York: Thieme Publishing Group.
- Andreetta, M. D., Adams S. G, Dykstra, A. D, Jog, M. (2016). Evaluation of speech amplification devices in Parkinson's disease. American Journal of Speech-Language Pathology, 25, 29–45. doi: 10.1044/2015_ajslp-15-0008
- Bertrand, A. N. (2009). Speech-language pathologists decision making pertaining to speech amplification devices: A survey (Master's thesis, Texas A&M University-Kingsville).
- Logemann, J. A., Fisher, H. B., Boshes, B., & Blonsky, E. R. (1978). Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. The Journal of Speech and Hearing Disorders, 43(1), 47–57. doi:10.1044/jshd.
- Nussbaum, R. L. & Ellis, C. E. (2003). Alzheimer's disease and Parkinson's disease. *New* England Journal of Medicine, 348(14), 1356–1364. General PD. doi:10.1056/ nejm2003ra020003
- Sapir, S. (2014). Multiple factors are involved in the dysarthria associated with Parkinson's disease: a review with implications for clinical practice and research. Journal of Speech, Language, and Hearing Research, 57(4), 1330–1343.